The MICs of AM, KM, and CAP were determined by the agar dilution method according to CLSI guidelines [41] on Middlebrook 7H10 agar supplemented Niraparib with 10% OADC and various concentrations of drug (0, 2, 4, 8, 16, 32, and 64 μg/ml). AK, KM, and CAP were purchased from Sigma Aldrich (Germany). The MIC was defined as the lowest concentration of drug that inhibited growth (>99%) after 4 weeks of incubation at 37°C. M. tuberculosis H37Rv ATCC 27294 was used as the susceptible control strain. Three independent experiments were performed for each strain. Acknowledgements

This study was financially supported by the Faculty of Science, King Mongkut’s Institute of Technology Ladkrabang (KMITL) and the Drug-Resistant Tuberculosis Research Fund, INCB028050 Siriraj Foundation, Faculty of Medicine Siriraj Hospital, Mahidol University. A. Sowajassatakul is also thankful for a scholarship for the Ph.D. Program that was provided by the Thailand Graduate Institute SN-38 in vivo of Science and Technology (TGIST), National Science and Technology Development Agency (NSTDA). Electronic supplementary material Additional file 1: Table S1: Genetic characterization of resistance genes and MIC values

for amikacin, kanamycin and capreomycin in 29 KM-resistant clinical isolates of M. tuberculosis. (DOC 84 KB) Additional file 2: Table S2: Genetic characterization of resistance genes and MIC values for amikacin, kanamycin and capreomycin in 27 AK- and KM-susceptible clinical isolates of M. tuberculosis. (DOC 76 KB) References 1. WHO: Global tuberculosis report. 2013. WHO/HTM/TB/2013.11. Geneva. 2013 WHO/HTM/TB/2013.11. Geneva. 2013 2. Blakemore R, Story E,

Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D: Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010,48(7):2495–2501. 10.1128/JCM.00128-10289749520504986CrossRefPubMedCentralPubMed 3. Boehme CC, Nabeta P, Hillemann D, Nicol Nutlin-3 datasheet MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD: Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010,363(11):1005–1015. 10.1056/NEJMoa0907847294779920825313CrossRefPubMedCentralPubMed 4. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NTN, Jones-Lόpez EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D: Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010,48(1):229–237. 10.1128/JCM.01463-09281229019864480CrossRefPubMedCentralPubMed 5.